Background. Ovarian cancer is usually diagnosed in an advanced stage and the present clinical and diagnostic molecular markers for early OC screening are insufficient. The aim of this study was to identify potential relationship between the hypodontia and epithelial ovarian cancer (EOC).
Patients and methods. A retrospective study was conducted on 120 patients with EOC treated at the Department of Gynaecologic and Breast Oncology at the University Clinical Centre and 120 gynaecological healthy women (control group) of the same mean age. Women in both groups were reviewed for the presence of hypodontia and the patients with EOC also for clinicopathological characteristics of EOC according to hypodontia phenotype.
Results. Hypodontia was diagnosed in 23 (19.2%) of patients with EOC and 8 (6.7%) controls (p = 0.004; odds ratio [OR] = 3.32; confidence interval [CI], 1.42-7.76). There was no statistically significant difference in patients with EOC with or without hypodontia regarding histological subtype (p = 0.220); they differed in regard to FIGO stage (p = 0.014; OR =3.26; CI, 1.23-8.64) and tumour differentiation grade (p = 0.042; OR = 3.1; CI, 1.01-9.53). Also, bilateral occurrence of EOC was more common than unilateral occurrence in women with hypodontia (p = 0.021; OR = 2.9; CI, 1.15-7.36). We also found statistically significant difference between the ovarian cancer group and control group in presence of other malignant tumours in subjects (p < 0.001).
Conclusions. The results of the study suggest a statistical association between EOC and hypodontia phenotype. Hypodontia might serve as a risk factor for EOC detection.
1. Cancer in Slovenia 2010. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2011. p. 37.
2. Cancer Research UK. Statistical Information Team; 2012. Available at: http:/ www.info.cancerresearchuk.org/cancerstats
3. United States cancer statistics: 1999-2008 incidence and mortality Wbbased report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2010. Available at: http://www.cdc.fov/uscs
4. Zhang B, Cai FF, Zhong XY. An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol 2011; 158: 119-23.
5. Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huetter PC, Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radio Graphics 2011; 31: 625-46.
6. Paulsen T, Kærn J, Kiærheim K, Tropé C, Tretli S. Symptoms and referral of women with epithelial ovarian tumors. Int J Gynecol Obstet 2005; 88: 31-7.
7. Wikborn C, Pettersson F, Silfverswärd C, Moberg PJ. Symptoms and diagnostic difficulties in ovarian epithelial cancer. Int J Gynecol Obstet 1993; 42: 261-4.
8. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systemetis review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998; 105: 493-9.
9. Takač I, Arko D. Diagnosis and treatment of ovarian cancer. In: Štabuc B, editor. Gynecological cancer/ XVI. Course in memoriam dr. Dušana Reje. Ljubljana: Zveza slovenskih društev proti raku; 2008. p. 41-8.
10. Benedet JL. Progres in gynecologic cancer detection and treatment. Int J Gynecol Obstet 2000; 70: 135-47.
11. Bolton KL, Ganda C, Berchuck A, Pharaoh PDP, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC). J Intern Med 2012; 271: 366-78.
20. Mostowska A, Biedziak B, Jagodzinski PP. Axis inhibition protein 2 (AXIN2) polymorphisms may be a risk factor for selective tooth agenesis. J Hum Genet 2006; 51: 262-6.
21. Lammi L, Arte S, Somer M, Järvinen H, Lahermo P, Thesleff I, et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 2004; 74: 1043-50.
22. Schmid S, Bieber M, Zhang F, Zhang M, He B, Jablons D, et al. Wnt and Hedgehog gene pathway expression in serous ovarian cancer. Int J Gynecol Cancer 2011; 21: 975-80.
23. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001; 61: 8247-55.
24. Benedet JL. Staging classifications and practice guidelines for gynecologic cancer. Int J Gynecol Obstet 2000; 70: 207-312.
25. Lopes NN, Petrilli AS, Caran Em, França CM, Chilvarquer I, Lederman H. Dental abnormalities in children submitted to antineoplastic therapy. J Dent Child 2006; 73: 210-3.
26. Küchler EC, Lips A, Tannure PN, Ho B, Costa MC, Granjeiro JM, et al. Tooth agenesis association with self-reported family history of cancer. J Dent Res 2013; 92: 149-55.
27. Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, Kolligs FT, et al. Role of ß- Catenin /T- Cell Factor-regulate genes in ovarian endometrioid adenocarcinoma. Am J Pathol 2002; 160: 1229-38.
28. Chalothorn LA, Beeman CS, Ebersole JL, Kluemper GT, Hicks EP, Kryscio RJ, et al. Hypodontia as a risk marker for epithelial ovarian cancer: a casecontroled study. J Am Dent Assoc 2008; 139: 163-9.
29. Fekonja A. Hypodontia prevalence over four decades in Slovenian population. J Esthet Restor Dent 2013; doi: 10.1111/jerd.12076. [Epub ahead of print].
30. Lurie G, Wilkens LR, Thompson PJ, Matsuno RK, Carney ME, Goodman MT. Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: a case analysis. Gynecol Oncol 2010; 119: 278-84.
31. But I. DNA ploidy and CA 125 in serous ovarian carcinoma [Doctoral Thesis]. Ljubljana: Faculty of Medicine, University of Ljubljana; 1998.